Haemonetics (HAE) reported fiscal 2027 Q1 earnings on August 6, 2026. The company delivered a strong start to the fiscal year, with top-line performance exceeding analyst consensus. Consequently, management raised its full-year revenue and organic growth guidance, signaling confidence in sustained momentum across its diversified business segments despite modest declines in bottom-line profitability.
Revenue
Total revenue for HaemoneticsHAE-- increased by 5.6% to $339.38 million in the first quarter of 2027, up from $321.39 million in the prior-year period, effectively beating estimates by $11.11 million. This consolidated growth was driven by distinct performance across its operational units: the Apheresis segment contributed $191.32 million, while the Plasma division generated $155.52 million. The MedSurg segment reported $148.06 million in revenue, and Blood Management Technologies accounted for $88.12 million. Additionally, Interventional Technologies brought in $59.94 million, with the "Other" category adding $35.79 million, culminating in the total net revenues of $339.38 million.
Earnings/Net Income
Haemonetics's EPS rose 2.8% to $0.73 in 2027 Q1 from $0.71 in 2026 Q1, marking continued earnings growth. Meanwhile, the company's net income declined to $33.01 million in 2027 Q1, down 3.0% from $34.03 million reported in 2026 Q1. Although reported earnings per share showed modest improvement, the decline in net income reflects higher interest expenses and unfavorable foreign exchange impacts, indicating that underlying operational gains were partially offset by financial headwinds.
Price Action
The stock price of Haemonetics has edged down 0.87% during the latest trading day, has edged up 0.24% during the most recent full trading week, and has jumped 13.54% month-to-date.
Post-Earnings Price Action Review
A review of the immediate market reaction reveals a muted response to the earnings release. On August 7, 2026, the day following the August 6, 2026, earnings announcement, Haemonetics stock exhibited a price change of 0%, despite reporting total revenue of $339.38 million. While a statistically meaningful 30-day backtest on revenue misses is not feasible due to the limited dataset containing only this single clean earnings event, the immediate zero-percent reaction suggests that the market had likely priced in the positive guidance revision and revenue beat. To construct a robust backtest, one would require a broader historical dataset including all earnings dates, clear definitions of revenue misses, and corresponding 30-day returns to avoid cherry-picking, rather than relying on this single data point.
CEO Commentary
Chris Simon, Haemonetics’ Chief Executive Officer, highlighted a robust fiscal 2027 start, driven by gaining plasma market share, sustaining momentum in Blood Management Technologies, and returning Interventional Technologies to growth. He emphasized that the company’s evolved portfolio, transformed operating model, and disciplined execution are strengthening its competitive position and demonstrating durable growth across diversified businesses. Simon expressed confidence in Haemonetics’ ability to deliver sustainable long-term growth and shareholder value, noting that the raised full-year guidance reflects the company’s strong positioning amidst these operational improvements and strategic advancements.
Guidance
Haemonetics raised its full-year fiscal 2027 guidance, increasing the reported revenue growth range from 4–7% to 5–8%. Organic revenue growth guidance was also upgraded, moving from 3–6% to 4–7%. The company maintained its adjusted operating margin guidance, expecting an expansion of 50 to 100 basis points year-over-year. Adjusted earnings per diluted share are expected to grow comparably to reported revenue. Free cash flow conversion is projected to remain stable at approximately 80%. The guidance continues to account for a 53rd week impact of roughly 2% and currency fluctuations between 0–1%, with organic growth including nominal historical pre-acquisition revenue of Vivasure for comparable performance analysis.
Additional News
Haemonetics recently announced its quarterly dividend details, with an ex-dividend date set for August 7, 2026. This dividend declaration underscores the company's commitment to returning capital to shareholders amidst its strong cash flow generation. In related corporate developments, the market has focused on the successful rollout of the Persona Plus system within the plasma segment, which is delivering yield improvements exceeding 5% for early adopters. Furthermore, attention has been drawn to the expansion of the VASCADE MVP XL indication in the MedSurg segment, driving low double-digit growth in vascular closure solutions. These product-level advancements are critical as the company navigates external cost pressures, including higher freight and material inflation, while aiming to maintain its projected free cash flow conversion rates.
